特发性肺纤维化与阻塞性睡眠呼吸暂停

doi:10.16138/j.1673-6087.2021.02.004

摘要/Abstract

中图分类号:

R563.5

马德东, 赵恩琪, 浦英. 特发性肺纤维化与阻塞性睡眠呼吸暂停[J]. 内科理论与实践, 2021, 16(02): 84-87.

参考文献 28

[1]	Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study[J]. Lancet Respir Med, 2015, 3(4):310-318. doi: 10.1016/S2213-2600(15)00043-0 pmid: 25682233
[2]	陈曦, 伍俊. 特发性肺纤维化的机制与治疗[J]. 生命的化学, 2020, 40(3): 329-336.
[3]	Li D, Wang B, Liu Y, et al. Prevalence and impact of comorbid obstructive sleep apnoea in diffuse parenchymal lung diseases[J]. PLoS One, 2021, 16(2): e0246878. doi: 10.1371/journal.pone.0246878 URL
[4]	Mavroudi M, Papakosta D, Kontakiotis T, et al. Sleep disorders and health-related quality of life in patients with interstitial lung disease[J]. Sleep Breath, 2018, 22(2): 393-400. doi: 10.1007/s11325-017-1579-1 pmid: 29038949
[5]	Pihtili A, Bingol Z, Kiyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease[J]. Sleep Breath, 2013, 17(4): 1281-1288. doi: 10.1007/s11325-013-0834-3 pmid: 23563999
[6]	Zhang XL, Dai HP, Zhang H, et al. Obstructive sleep apnea in patients with fibrotic interstitial lung disease and COPD[J]. J Clin Sleep Med, 2019, 15(12): 1807-1815. doi: 10.5664/jcsm.8090 pmid: 31855166
[7]	Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824. doi: 10.1164/rccm.2009-040GL URL
[8]	Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective[J]. Am J Respir Crit Care Med, 2002, 165(9): 1217-1239. doi: 10.1164/rccm.2109080 URL
[9]	Cardoso AV, Pereira N, Neves I, et al. Obstructive sleep apnoea in patients with fibrotic diffuse parenchymal lung disease-characterization and treatment compliance assessment[J]. Can J Respir Ther, 2018, 54(2): 35-40. doi: 10.29390/cjrt-2018-005 URL
[10]	Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis[J]. Chest, 2009, 136(3): 772-778. doi: S0012-3692(09)60546-8 pmid: 19567497
[11]	Şahin Duyar S, Uzel Şener M, Akıncı Özyürek B, et al. An integrated approach toward the clinical and polysomnographic characteristics of OSA accompanying IPF[J]. Turk Thorac J, 2020, 21(5): 334-339. doi: 10.5152/TurkThoracJ.2020.19002 URL
[12]	Heinzer RC, Stanchina ML, Malhotra A, et al. Lung vo-lume and continuous positive airway pressure requirements in obstructive sleep apnea[J]. Am J Respir Crit Care Med, 2005, 172(1): 114-117. doi: 10.1164/rccm.200404-552OC URL
[13]	Sériès F, Cormier Y, Lampron N, et al. Increasing the functional residual capacity may reverse obstructive sleep apnea[J]. Sleep, 1988, 11(4): 349-353. pmid: 2974620
[14]	Chrousos GA, Kattah JC, Beck RW, et al. Side effects of glucocorticoid treatment[J]. JAMA, 1993, 269(16): 2110-2112. doi: 10.1001/jama.1993.03500160080036 URL
[15]	Bosi M, Milioli G, Fanfulla F, et al. OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in IPF[J]. Lung, 2017, 195(5): 643-651. doi: 10.1007/s00408-017-0031-4 URL
[16]	Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis[J]. J Clin Sleep Med, 2013, 9(6): 593-601. doi: 10.5664/jcsm.2758 pmid: 23772193
[17]	Mermigkis C, Mermigkis D, Varouchakis G, et al. CPAP treatment in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea-therapeutic difficulties and dilemmas[J]. Sleep Breath, 2012, 16(1): 1-3. doi: 10.1007/s11325-010-0476-7 URL
[18]	da Rosa DP, Forgiarini LF, Baronio D, et al. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver[J]. Mediators Inflamm, 2012, 2012: 879419.
[19]	Weng T, Poth JM, Karmouty-Quintana H, et al. Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2014, 190(12): 1402-1412. doi: 10.1164/rccm.201404-0744OC URL
[20]	Tiruvoipati R, Lewis D, Haji K, et al. High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients[J]. J Crit Care, 2010, 25(3): 463-468. doi: 10.1016/j.jcrc.2009.06.050 URL
[21]	Tarraubella N, Sánchez-de-la-Torre M, Nadal N, et al. Management of obstructive sleep apnoea in a primary care vs sleep unit setting: a randomised controlled trial[J]. Thorax, 2018, 73(12): 1152-1160. doi: 10.1136/thoraxjnl-2017-211237 pmid: 30064993
[22]	Shepherd K, Hillman D, Holloway R, et al. Mechanisms of nocturnal gastroesophageal reflux events in obstructive sleep apnea[J]. Sleep Breath, 2011, 15(3): 561-570. doi: 10.1007/s11325-010-0404-x pmid: 20711680
[23]	Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis[J]. Sleep Breath, 2015, 19(1): 385-391. doi: 10.1007/s11325-014-1033-6 URL
[24]	Kohler M, Bloch KE, Stradling JR. Pharmacological approaches to the treatment of obstructive sleep apnoea[J]. Expert Opin Investig Drugs, 2009, 18(5): 647-656. doi: 10.1517/13543780902877674 URL
[25]	Canora A, Nicoletta C, Ghinassi G, et al. First description of the hyperpnea-hypopnea periodic breathing in patients with interstitial lung disease-obstructive sleep apnea: treatment implications in a real-life setting[J]. Int J Environ Res Public Health, 2019, 16(23): 4712. doi: 10.3390/ijerph16234712 URL
[26]	姚娟娟. 无创呼吸机恒流模式的作用机制验证及舒适性评估[D]. 山东大学, 2020.
[27]	Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis[J]. Eur Respir J, 2017, 49(6): 1601934. doi: 10.1183/13993003.01934-2016 URL
[28]	李庆云, 宋爱玲. 对特发性肺纤维化合并阻塞性睡眠呼吸暂停的新认识[J]. 中华医学杂志, 2019, 99(6): 416-418.

特发性肺纤维化与阻塞性睡眠呼吸暂停

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周思锋, 徐海舒, 范欣生. 基于不同生物样本代谢组学的OSAHS生物标志物研究进展[J]. 诊断学理论与实践, 2022, 21(04): 535-540.
[2]	许轶明, 沈宏华, 张音, 任蕾. 阻塞性睡眠呼吸暂停与卒中[J]. 内科理论与实践, 2021, 16(04): 276-281.
[3]	胡克, 杨海珍, 岳芳. 新型冠状病毒肺炎疫情对阻塞性睡眠呼吸暂停诊治的影响及对策[J]. 内科理论与实践, 2021, 16(02): 73-75.
[4]	王利娟, 王蓓. 阻塞性睡眠呼吸暂停与眼部疾病研究进展[J]. 内科理论与实践, 2021, 16(02): 134-137.
[5]	李庆云, 李诗琪, 周剑平. 阻塞性睡眠呼吸暂停与吸烟的交互影响[J]. 内科理论与实践, 2021, 16(02): 76-79.
[6]	王建丽, 张立强. 睡眠呼吸障碍与肺动脉高压[J]. 内科理论与实践, 2021, 16(02): 80-83.
[7]	崔小川, 张希龙. 阻塞性睡眠呼吸暂停低通气综合征与支气管哮喘[J]. 内科理论与实践, 2021, 16(02): 93-96.
[8]	许磊, 许轶明, 沈宏华, 张音, 任蕾. 阻塞性睡眠呼吸暂停合并卒中对睡眠及神经认知功能的影响[J]. 内科理论与实践, 2021, 16(02): 97-102.
[9]	陈孚, 李震, 周勇, 王勇. 肥胖合并呼吸衰竭病人的减重代谢手术（附1例报告）[J]. 外科理论与实践, 2020, 25(05): 440-441.
[10]	陈燕, 李红鹏, 李诗琪, 张柳, 沈继敏, 李庆云,. 冠心病合并阻塞性睡眠呼吸暂停-慢性阻塞性肺疾病重叠综合征1例[J]. 内科理论与实践, 2019, 14(06): 379-380.
[11]	张姗, 张希龙, 黄茂, 孟自力, 徐靖,. 比较不同严重程度阻塞性睡眠呼吸暂停低通气综合征夜间瞬时血压变异性特点及诱发因素[J]. 内科理论与实践, 2019, 14(05): 303-307.
[12]	杭燕萍, 赵明明, 张希龙,. 阻塞性睡眠呼吸暂停综合征与肺血栓栓塞症[J]. 内科理论与实践, 2019, 14(04): 265-268.
[13]	苏梅, 曹娟, 魏建军, 张希龙,. 三水平和双水平正压通气对合并中重度阻塞性睡眠呼吸暂停的肥胖低通气综合征患者疗效的比较[J]. 内科理论与实践, 2019, 14(04): 230-234.
[14]	盛维伟, 董艳彬, 金琳羚, 张希龙,. 阻塞性睡眠呼吸暂停综合征严重度与血小板参数相关性的探讨[J]. 内科理论与实践, 2019, 14(01): 35-38.
[15]	杨天芸, 刘松,. 阻塞性睡眠呼吸暂停:难治性哮喘和重症哮喘的危险因素之一[J]. 内科理论与实践, 2019, 14(01): 26-29.